Company news
Initiator Pharma A/s (OMXSTO:INIT) news
Initiator Pharma A/s news releases on 6ix. Latest, Sep 14, 2026: Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
Press releases & updates
Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
September 14, 2026
Initiator Pharma secures two European patents for pudafensine
August 19, 2026
Initiator Pharma attends BIO 2026 in San Diego
June 23, 2026
Initiator Pharma A/S – Resolutions of the annual general meeting 2026
May 29, 2026
Initiator Pharma A/S calls for the Annual General Meeting
May 12, 2026
Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
May 8, 2026
Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
April 28, 2026
Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued
April 21, 2026
Initiator Pharma To Fully Prioritize Pudafensine
April 17, 2026
Initiator Pharma to present at Redeye Healthcare Day 2026
April 10, 2026
INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026
March 11, 2026
INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data due in late 2024
March 9, 2026
Initiator Pharma (Q4 Review): Dosing underway in phase IIa study
February 20, 2026
Initiator Pharma Granted European Patent For Pudafensine in FSD
February 18, 2026
Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco
December 23, 2025
INIT: Advanced clinical pipeline and secured major financing, with focus on vulvodynia and ED markets
November 21, 2025
INIT: First-in-class therapy for vulvodynia enters pivotal trial, targeting a multibillion-euro market
November 17, 2025
Initiator Pharma Gets UK CTA Approval For Phase 2a Study
November 3, 2025
Initiator Pharma A/S: Quarterly Trading Report 2025 Q3
October 3, 2025
INIT: Pudafensine advances to Phase II for vulvodynia, targeting major unmet needs in women's health
September 25, 2025
INIT: Pudafensine advanced to Phase IIa for vulvodynia, with strong funding and reduced Q2 losses
August 22, 2025
INIT: Q1 2025 saw reduced losses and clinical progress in ED, FSD, and pain programs
May 9, 2025
INIT: Reduced losses and clinical progress in ED and FSD position Initiator Pharma for future growth
February 28, 2025
INIT: Reduced losses and strong clinical progress for pudafensine mark Q3 2024 for Initiator Pharma
November 29, 2024
INIT: Reduced losses, new patents, and clinical progress position Initiator Pharma for future growth
August 23, 2024